iCAC Device vs AVIEW
AI Verdict
Choose iCAC Device if…
Choose iCAC Device if your primary objective is the opportunistic identification and quantification of coronary artery calcium from routine, non-contrast, non-gated chest CT scans that were not initially ordered for cardiac assessment. This tool is ideal for facilities seeking to leverage existing imaging data to provide adjunctive cardiovascular risk information to radiologists, focusing specifically on efficient CAC burden estimation for early disease detection.
View iCAC Device →Choose AVIEW if…
Choose AVIEW if your institution requires a comprehensive AI platform offering multi-faceted diagnostic support across lung health and cardiology, including advanced solutions for lung cancer, COPD, and detailed coronary artery calcification scoring. This platform is best suited for environments needing features like AI-powered lung nodule detection and characterization, emphysema quantification, and comprehensive CAC scoring (Agatston, volume, mass) with risk stratification, alongside robust 3D visualizations and integrated reporting for streamlined radiology workflows and patient follow-up.
View AVIEW →For a physician evaluating AI tools for medical imaging, the iCAC Device from Bunkerhill Health and Coreline Soft’s AVIEW platform offer distinct advantages. The iCAC Device specializes in the opportunistic detection and quantification of coronary artery calcium (CAC) from routine, non-contrast, non-gated chest CT scans. It excels at providing precise Agatston unit estimates and visual segmentations of CAC, making it ideal for integrating cardiovascular risk assessment into existing radiology workflows without requiring dedicated cardiac CTs. Its strength lies in its focused application for early cardiovascular disease detection.
AVIEW, on the other hand, presents a more comprehensive AI platform. While it also offers coronary artery calcium scoring (Agatston, volume, mass), its capabilities extend significantly into pulmonology, including AI-powered lung nodule detection and characterization, emphysema quantification, and interstitial lung disease pattern analysis. The key practical difference is AVIEW’s broader diagnostic scope across multiple thoracic pathologies versus iCAC’s specialized focus on CAC. Physicians primarily concerned with integrating opportunistic CAC screening into their practice with minimal workflow disruption might favor the iCAC Device. However, those seeking a more expansive AI solution for comprehensive thoracic imaging analysis, encompassing both cardiac and pulmonary conditions, would find AVIEW to be the more versatile choice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | iCAC Device | AVIEW |
|---|---|---|
| Pricing | Contact for pricing | Subscription; one-off payment |
| Deployment | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWAVIEW offers explicit features like workflow automation, 3D visualizations, comprehensive PDF reports, and follow-up registration with nodule matching, indicating a more comprehensive and streamlined user experience for radiologists managing multiple conditions. While iCAC integrates with PACS/DICOM and EHRs, AVIEW's detailed feature set suggests a broader focus on enhancing daily radiological workflows.
Clinical Value
AVIEWAVIEW provides comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification, including detailed analyses like Lung-RADS scoring, emphysema quantification, and ILD pattern analysis. In contrast, iCAC focuses solely on detecting and quantifying coronary artery calcium, making AVIEW's clinical utility significantly broader across multiple specialties.
Pricing & Value
AVIEWAVIEW offers transparent pricing models, including subscription and one-off payment options based on installations or users, allowing potential customers to better understand cost structures. iCAC, however, provides no pricing details and requires direct contact with the vendor, which offers less transparency and makes value assessment more challenging.
Enterprise Readiness
AVIEWAVIEW explicitly states HIPAA compliance and offers highly flexible deployment options, including cloud-based, hybrid, local hardware, and virtualized solutions, catering to diverse enterprise IT and security requirements. iCAC requires contacting the vendor for HIPAA compliance and BAA details, and its deployment options appear less varied.
Innovation
AVIEWWhile iCAC innovates by opportunistically detecting CAC from routine, non-contrast, non-gated chest CT scans, AVIEW demonstrates a broader and deeper range of AI innovation. It applies AI to multiple complex conditions, including detailed lung nodule characterization with Lung-RADS, emphysema quantification, ILD pattern analysis, and automated segmentation, showcasing a more comprehensive and advanced AI platform.
Support & Docs
TieNeither the provided structured facts nor general web searches for publicly available information offer sufficient detail to definitively compare the quality or availability of support and documentation for either tool. Therefore, based on the available information, it is not possible to distinguish a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | iCAC Device | AVIEW |
|---|---|---|
| Primary Focus | Detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection. | Offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans. |
| Company | Bunkerhill Health | Coreline Soft Co. |
| Coronary Artery Calcium (CAC) Analysis | Estimates presence and quantity of CAC, analyzes routine, non-contrast, non-gated chest CT scans, delivers exact and four-category quantitative estimates of CAC burden in Agatston units. | CAC scoring (Agatston, volume, mass score, risk stratification), automated segmentation of coronary arteries. |
| Lung Analysis Capabilities | Not specified | AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score), Emphysema quantification and low attenuation area (LAA) analysis, Automated segmentation of lung lobes, airways, vessels, Interstitial Lung Disease (ILD) pattern analysis. |
| Integration | Integrates with PACS or DICOM router, integrates with EHRs via the Carebricks platform. | Workflow automation and integration with PACS/RIS/CIS. |
| Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring iCAC Device and AVIEW.